

ASX: CVB

30 April 2025

Appendix 4C & quarterly activity report – period ended 31 March 2025

Summary of key activities

- During Q3 FY25, CurveBeam AI received purchase orders (POs) for seven (7) devices, four (4) of which were HiRise™.
- Total POs for Q3 FY25 were up 40% from five (5) in the prior corresponding period (pcp).
- Twenty (20) POs have been received for the nine (9) month period to 31 March 2025 versus twelve (12) in the pcp, up 67%.
- During the quarter, the Company pursued a vendor financing facility, and the Company has entered into a non-binding term sheet with an international financing partner for an ~A\$18m (€10m) facility. Contract completion is expected in Q4 FY25 post final due diligence. This facility will allow the Company to offer leasing deals to support direct sales in Europe and other key markets. It will also allow the Company to immediately finance existing leased devices which will result in near term positive cash inflows.
- Cash at the end of Q3 FY25 was A\$4.9m, with receivables plus cash collection (as at the end of Q3 FY25) from previously obtained POs of A\$7.9m. This is expected to result in a near-term cash position for the Company of A\$13.8m.
- Cash from previous POs are collected as devices are installed and based on the current installation schedule, the Company expects Q4 FY25 will be cashflow positive. Given the expected cash inflows from device installations and other targeted initiatives, the Board is confident in the Company's cash position.
- The Company is continuing to complete validation of the enhanced HiRise™, required for custom protocols for hip and knee robotic surgical systems. As announced on 31 March 2025, the Company submitted further validation data and substantive accompanying documentation to the vendor, including updated instructions for use to include HiRise™. The Company is confident this submission meets the requirements to complete validation and awaits the vendor review and its conclusion.


Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB, "CurveBeam AI" or the "Company"), a fully integrated developer and manufacturer of point-of-care specialised medical imaging (CT) equipment, supported by a range of AI enabled SaaS-based clinical assessment solutions, is pleased to announce its Appendix 4C and quarterly activity report for the period ended 31 March 2025 (Q3 FY25).

Purchase Orders and Receipts

During Q3 FY25, CurveBeam AI received seven (7) purchase orders (POs), representing a 40% increase over the prior corresponding period of five (5) POs. While eight (8) POs were received, an awarded tender in Thailand had to be withdrawn due to earthquake damage to the hospital. The first three quarters of FY25 saw a total of twenty (20) POs, up 67% compared to first three quarters of FY24 of twelve (12) POs.

Receipts from customers for Q3 FY25 were A\$1.5m, down from A\$2.6m in Q2 FY25 reflecting fewer device installations. A significant increase in scheduled installations are planned for 4Q FY25 and the Company expects Q4 FY25 will be cashflow positive.

Device Purchase Orders	Q1 FY24	Q2 FY24	Q3 FY24		Q1 FY25	Q2 FY25	Q3 FY25
US	2	2	2		1	8	4
Rest of World	1	2	3		2	2	3
Total	3	4	5		3	10	7



Enhanced HiRise™ Validation

During the quarter, the Company continued to progress validation of the enhanced HiRise™ for a major robotic aided surgical system. The Company has submitted matched HiRise™ and multidetector CT (MDCT) patient scans where HiRise™ data achieved all required performance criteria, meeting or exceeding the MDCT metrics that were used as a control. The Company has also submitted to the vendor substantive accompanying documentation, including updated instructions for use to include HiRise™. The Company is confident this submission meets the requirements to complete validation and awaits the vendor team’s review and its conclusion.

Presentations to investors at Healthcare Conferences

During the quarter, CurveBeam AI CEO and MD, Greg Brown, presented as part of the Euroz Hartleys and NWR Virtual Healthcare Conferences, with both events seeing a range of life sciences companies present to an audience of institutional and sophisticated investors.

Cashflow from Operations and Runway

Cash used in operations for Q3 FY25 was A\$4.4m versus A\$4.5m in Q3 FY24 (pcp) and A\$2.7m in Q2 FY25.

Cash outflows at item 1.2 (below) totalled A\$5.9m down from A\$6.8m pcp, and A\$7.1m in Q2 FY25. Material points to note in respect of cash outflows include:

1. Product Manufacturing and Operating Costs were down A\$0.6m against Q2, with inventory purchases reduced for the quarter, and deliveries were filled from existing inventory.
2. Staff Costs were down A\$0.6m against Q2, that included seven fortnights versus six in Q3.

Cash used in operations for Q3 was A\$4.4m, up from A\$2.7m in Q2, with Q2 including A\$1.8m in R&D tax incentives. The Q3 to Q2 variance in receipts from customers was directly offset by reductions in cash outflows summarised above.

Appendix 4C Comparative Summary - FY2024 & FY2025

	FY2024				FY2025		
	Q1	Q2	Q3	Q4	Q1	Q2	Q3
	Actual						
1.1 Receipts from Customers	1,655	1,329	2,204	1,953	2,410	2,589	1,545
1.2 Payments for:							
a) R&D	(161)	(124)	(340)	(156)	(376)	(257)	(304)
b) Product manufacturing and operating costs	(2,628)	(1,143)	(1,647)	(1,357)	(2,582)	(1,990)	(1,409)
c) Advertising & Marketing	(139)	(472)	(497)	(242)	(392)	(260)	(365)
d) Leased Assets							
e) Staff costs	(3,442)	(4,362)	(3,197)	(3,315)	(2,926)	(3,562)	(2,989)
f) Admin & corporate costs	(2,592)	(2,244)	(1,102)	(1,515)	(939)	(1,069)	(891)
Subtotal - Outflows	(8,962)	(8,345)	(6,783)	(6,585)	(7,215)	(7,138)	(5,958)
1.3 Dividends received							
1.4 Interest Received	57	146	104	67	58	68	46
1.5 Interest & other costs of finance paid						(86)	
1.6 Income Taxes Paid							
1.7 Government Grants & Tax Incentives		1,576				1,833	
1.8 Other							
Subtotal - Other	57	1,722	104	67	58	1,815	46
1.9 Cash from (used in) Operations	(7,250)	(5,294)	(4,475)	(4,565)	(4,747)	(2,734)	(4,367)
2.6 Cash flows from investing activities	(78)	(15)	319	(547)	(20)	-	-
3.1 Cash flows from financing activities	23,857	(998)	685	(126)	8,723	991	496
4.5 Exchange Movements	(143)	(279)	293	(93)	(272)	455	(15)
4.1 Opening Cash	5,158	21,544	14,958	11,780	6,448	10,132	8,844
Net increase (decrease) in cash in the period	16,386	(6,586)	(3,178)	(5,331)	3,684	(1,288)	(3,886)
4.6 Closing Cash	21,544	14,958	11,780	6,449	10,132	8,844	4,958
Quarters of Cash (Operating)	(2.97)	(2.83)	(2.63)	(1.41)	(2.13)	(3.23)	(1.14)

Cash at the end of Q3 FY25 of A\$4.9m resulted in a calculation of quarters of funding remaining at item 8.5 of the Appendix 4C of 1.14 quarters, however the Company's expectation is for cash to increase in Q4, with scheduled device installations, receipts and other cashflows.

With anticipated cashflows for Q4, the Board of the Company remains confident in its cash position, with the quarters of funding based on a Q3 result not representative of expectations for Q4. The Company presently expects Q4 will be cashflow positive.

During the quarter, the Company pursued a vendor financing opportunity with a potential international financing partner to enable it to offer HiRise™ leasing deals for supporting direct sales in Europe and other key markets. The Company sees this as an important step in delivering more device placements. A non-binding term sheet for an ~A\$18m (€10m)¹ facility was signed in April and the Company is targeting execution of the binding contract later in Q4 FY25 post final

¹ Based on an exchange rate of EUR 0.56 to AUD\$1.00.

due diligence. The facility will also allow the Company to immediately finance existing leased devices which would result in positive cash inflows.

Cash at the end of Q3 FY25 was A\$4.9m, with receivables plus cash due from previous POs [as at the end of Q3 FY25] of A\$7.9m, the near-term cash available to the Company is expected to be A\$13.8m. The Company is also advancing other opportunities that may deliver further non-dilutive capital.

Use of Funds (Listing Rule 4.7C.2)

As stated in the Company's quarterly activity report for Q2, the funds outlined in the updated use of funds schedule included in the Pre-Quotation Disclosure released to ASX on 21 August 2023 are now fully acquitted. As such, the following use of funds statement remains unchanged from the prior quarter:

Use of Funds (\$000)	Per Pre- Quotation Disclosure*	% of funds raised	Use of Funds for the period to	% of funds used	
Sales and marketing	13,165	45%	6,041	21%	
New product development and R&D	4,203	14%	8,545	29%	
Intellectual property costs	1,947	7%	758	3%	
Costs of the Offer	3,469	12%	3,021	10%	
Other working capital	***	6,456	22%	10,875	37%
Total		29,240		29,240	

* As disclosed on Pre-Quotation Disclosure released on 21 August 2023, this reflects the Offer Proceeds of \$25,000k, along with \$4,240k cash on hand prior to receipt of Offer

** Use of Funds includes IPO proceeds from listing date through to the end of the current quarter.

*** Other working capital is comprised of the following items: Inventory, Corporate & Administration, Finance, Quality & Regulatory, Warranty/Technical Support, IT, and Lease Payments.

Payments to related parties (Listing Rule 4.7C.3)

In accordance with Listing Rule 4.7C.3 and as outlined in Section 6.1 of the Appendix 4C, the Company made payments to related parties totalling A\$226,000, comprising executive and non-executive directors' fees, salary, and superannuation.

Definitions

As previously noted, CurveBeam AI's key metrics are defined and interpreted as follows:

- Purchase order – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time.
- Receipts from customers – any cash consideration received from a customer by CurveBeam AI. This can include initial deposits required at the time of an order being placed.
- Revenue – Revenue is recognised after the device (e.g., HiRise™) is delivered, installed and training has been completed. Depending on the customer site requirements, there can be several months' delay from a signed purchase order to recognition of revenue. Thus, revenue may not be reflective of sales progress in each period.

The Company will report on POs and cash receipts in its Appendix 4C (quarterly) lodgements, while revenue will be reported in the Appendix 4E (full year report) and Appendix 4D (half year report).

Release approved by the Board of Directors.

About CurveBeam AI Limited

CurveBeam AI (ASX:CVB) develops, manufactures and sells specialised medical imaging (CT) scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to <https://curvebeamai.com>

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au